Literature DB >> 1645084

Importance of district of residence and known primary site for bowel cancer survival: analysis of data from Wessex Cancer Registry.

R M Pickering1, I R Chadwell, L Mountney.   

Abstract

STUDY
OBJECTIVE: The aim was to compare survival with colon and rectal cancer across the 10 districts of Wessex taking into account the age and sex of the individual.
DESIGN: The study was based on registrations on the Wessex Cancer Registry between 1979 and 1984 with colon and rectal cancer. Survival up to 31 December 1986 was examined using a Cox regression model; individuals surviving to the end of the follow up period were treated as censored in the analysis. Survival was examined in the first fortnight, the first month, and the first six months after registration separately. PARTICIPANTS: The data comprised 6239 residents of the Wessex Region who had been diagnosed with colon cancer and 3203 residents diagnosed with rectal cancer. For 140 cases survival data or age were missing and these cases were excluded.
MEASUREMENTS AND MAIN RESULTS: Results are presented in the format of a league table giving the order of districts from lowest to highest survival rates. No significant differences in survival are found between districts in relation to rectal cancer. We find that one or two districts have consistently high or low survival rates with colon cancer in various periods of follow up, but cannot differentiate between the districts in the centre of the list. Site unspecified is considered as an explanatory variable; it is more predictive than district, and it approaches the importance of age in explaining survival with colon cancer.
CONCLUSIONS: There are significant differences in survival with colon cancer between districts; however data on stage at registration are not available and we are unable to say whether the differences in survival are due to differences in stage at diagnosis or differences in survival with similar stage at diagnosis. We found that cases where the site of the cancer within the colon was not recorded on the register have significantly lower survival, and we suggest that site unspecified may be related to stage at diagnosis.

Entities:  

Mesh:

Year:  1992        PMID: 1645084      PMCID: PMC1059565          DOI: 10.1136/jech.46.3.266

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  6 in total

1.  Outcome-based equity in the treatment of colon cancer patients in Finland.

Authors:  M Hakama; S Karjalainen; T Hakulinen
Journal:  Int J Technol Assess Health Care       Date:  1989       Impact factor: 2.188

2.  Towards cheaper intravenous nutrition.

Authors:  J Macfie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-11

3.  The survival of patients with colorectal cancer treated in a regional hospital.

Authors:  P G Gill; P J Morris
Journal:  Br J Surg       Date:  1978-01       Impact factor: 6.939

4.  Long term survival analysis: the curability of breast cancer.

Authors:  S J Pocock; S M Gore; G R Kerr
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

5.  Geographical variation in cancer patient survival in Finland: chance, confounding, or effect of treatment?

Authors:  S Karjalainen
Journal:  J Epidemiol Community Health       Date:  1990-09       Impact factor: 3.710

6.  Delay in diagnosis and treatment of symptomatic colorectal cancer.

Authors:  H W Holliday; J D Hardcastle
Journal:  Lancet       Date:  1979-02-10       Impact factor: 79.321

  6 in total
  3 in total

1.  Socioeconomic circumstances and the risk of bowel cancer in Northern Ireland.

Authors:  F Kee; R Wilson; S Currie; J Sloan; R Houston; B Rowlands; J Moorehead
Journal:  J Epidemiol Community Health       Date:  1996-12       Impact factor: 3.710

2.  Survival after colon cancer 1973-1990 in Sweden. Convergence between catchment areas.

Authors:  P Blomqvist; A Ekbom; O Nyrén; U Krusemo; R Bergström; H O Adami
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

3.  Centralised treatment, entry to trials and survival.

Authors:  C A Stiller
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.